Ramona Optics Raises $25M Series A Led by ARCH Venture Partners

Ramona Optics Closes $25M Series A

Ramona Optics has raised a $25 million Series A round, the company announced on September 22, 2026. The round was led by ARCH Venture Partners, with participation from ND Capital, Overlap Holdings, Hamamatsu Ventures, Fall Line Capital, Stealthpoint Ventures, and Murchison Capital Partners.

The financing brings institutional capital behind a computational imaging platform that the company positions as a replacement for conventional microscopy at scale.

What Ramona Optics Does

Ramona Optics builds the Multi-Camera Array Microscope (MCAM), a computational imaging platform that pairs gigapixel optics with embedded AI to capture cellular-level detail across large samples in real time.

The company's benchtop systems are aimed at two distinct workflows:

• Vireo — live-cell imaging of cellular models
• Kestrel — imaging of small model organisms

According to the company, each unit replaces dozens of conventional microscopes. That framing is central to the commercial pitch: rather than scaling microscopy throughput by adding instruments, Ramona Optics consolidates imaging capacity into a single benchtop system.

Who It Serves

Ramona Optics targets universities, biotech companies, and pharmaceutical customers. These are environments where imaging throughput and consistency directly affect research timelines — from academic labs running high-volume screens to drug discovery teams that need cellular-level detail across large sample sets.

The combination of gigapixel optics and embedded AI is intended to deliver that detail in real time, rather than requiring the sample-by-sample passes typical of conventional microscope arrays.

The Investor Group

ARCH Venture Partners led the round, continuing its pattern of backing platform technologies in the life sciences tools space. The participating syndicate spans several investor profiles:

• ND Capital
• ARCH Venture Partners (lead)
• Overlap Holdings
• Hamamatsu Ventures
• Fall Line Capital
• Stealthpoint Ventures
• Murchison Capital Partners

Hamamatsu Ventures' participation is notable given the broader imaging and photonics ecosystem, though the company has not disclosed specific strategic terms.

Why This Round Matters

Microscopy is a mature category, but the bottleneck for many labs is not resolution — it is throughput. Capturing cellular-level detail across large samples in real time, without multiplying the number of instruments on a bench, addresses a workflow constraint that academic and industrial labs both face.

Ramona Optics' approach is to treat the instrument as a computational system rather than a purely optical one. Gigapixel optics capture the raw data; embedded AI processes it. The result, per the company, is a platform that scales with sample volume rather than with microscope count.

For biotech and pharmaceutical customers, that distinction matters most in screening and model-organism work, where sample volumes are high and imaging time is a limiting factor.

Stage and Positioning

This is a Series A round, placing Ramona Optics at the stage where platform companies typically move from technical validation toward commercial scale-up. The company has not disclosed revenue figures, customer names, or deployment counts.

What is disclosed is the round size, the lead investor, the participating syndicate, and the date. Those facts frame the company's near-term position: a $25 million Series A, led by ARCH Venture Partners, with a syndicate that includes both venture firms and a strategic investor with imaging-industry ties.

What to Watch

The company's stated focus is on replacing conventional microscope arrays in university, biotech, and pharmaceutical settings. The key questions for the coming period are commercial rather than technical: how quickly benchtop MCAM systems convert lab interest into installed units, and whether the Vireo and Kestrel product lines can establish repeatable deployment patterns across customer segments with very different procurement cycles.

For now, the funding itself is the headline. Ramona Optics has $25 million in new capital, a lead investor in ARCH Venture Partners, and a syndicate behind it.

Summary

• Company: Ramona Optics
• Headquarters: Durham, North Carolina
• Round: Series A
• Amount: $25,000,000 USD
• Date: September 22, 2026
• Lead investor: ARCH Venture Partners
• Participating investors: ND Capital, Overlap Holdings, Hamamatsu Ventures, Fall Line Capital, Stealthpoint Ventures, Murchison Capital Partners
• Platform: Multi-Camera Array Microscope (MCAM), pairing gigapixel optics with embedded AI
• Products: Vireo (live-cell imaging of cellular models), Kestrel (small model organisms)
• Customers: Universities, biotech, and pharmaceutical organizations